Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Bioventus Inc.NASDAQ: BVS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $11.21M fell 5.6% year over year, ahead of the -6.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.
Context
- Depreciation & amortization amounted to 8.3% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -5.6% holds above the trailing-twelve-month pace of -6.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 47.01M USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- +7.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.01M | -5.1% |
| FY2024 | 2024-12-31 | 49.56M | -13.6% |
| FY2023 | 2023-12-31 | 57.37M | +3.6% |
| FY2022 | 2022-12-31 | 55.4M | +58.8% |
| FY2021 | 2021-12-31 | 34.88M | — |
Depreciation & Amortization vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 depreciation & amortization of $46.35M is the 4th largest of the 9 companies compared; the peer median is $23.72M.
- Its year-over-year change of -6.6% is the 8th highest of 9, against a peer median of +6.4%.
- Depreciation & amortization amounts to 8.0% of revenue for BVS, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $573M | +3.2% | +1.5% | 9.3% | |
| LTM Mar 2026 | $153.07M | +3.8% | +8.7% | 9.3% | |
| LTM Mar 2026 | $136.43M | +43.1% | +37.4% | 16.5% | |
| LTM Mar 2026 | $46.35M | -6.6% | -5.3% | 8.0% | |
| LTM Mar 2026 | $30.95M | +45.2% | +35.9% | 6.0% | |
| LTM Mar 2026 | $16.5M | +94.2% | +54.4% | 4.2% | |
| LTM Mar 2026 | $5.54M | -27.5% | -26.6% | 4.8% | |
| LTM Mar 2026 | $4.68M | +9.1% | +59.3% | 3.8% | |
| LTM Jun 2026 | $1M | -5.9% | -5.2% | 1.3% | |
| Peer median (excluding BVS) | $23.72M | +6.4% | +22.3% | 5.4% | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 11.45M | (144.65M) | (121.2M) | (318K) | 27.27M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| Deferred Income Tax | (9.76M) | (46.66M) | (2.38M) | (5.39M) | (909K) |
| Stock-Based Compensation | 19.84M | 17.59M | 2.72M | 10.06M | 12.67M |
| Change in Working Capital | (15.15M) | (29.73M) | (3.18M) | (11.78M) | (13.84M) |
| Accounts Receivables | (20.05M) | (17.67M) | 10.06M | (10.67M) | (916K) |
| Inventory | 3.18M | (18.62M) | (5.99M) | (16.44M) | 8.57M |
| Accounts Payables | 0 | 0 | 0 | 0 | (19.81M) |
| Other Working Capital | 1.72M | 6.56M | (13.24M) | 15.32M | (1.68M) |
| Other Non-Cash Items | (18.28M) | 134.52M | 82.01M | (3.33M) | 1.77M |
| Operating Cash Flow | 22.99M | (13.54M) | 15.34M | 38.8M | 73.98M |
| Capital Expenditures | (20.89M) | (1.48M) | (7.36M) | (1.01M) | (2.56M) |
| Acquisitions (Net) | (262.87M) | 0 | 34.68M | 0 | (686K) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.37M) | (114.96M) | (11.51M) | 23.97M | 0 |
| Investing Cash Flow | (283.76M) | (116.44M) | 15.81M | 22.96M | (3.25M) |
| Debt Repayment | 166.2M | 59.62M | (23.26M) | (59.58M) | (42.91M) |
| Common Stock Issued | 109.41M | 5.82M | 778K | 2.44M | 2.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (367K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.88M) | (3.37M) | (4.17M) | 2.56M | (20.61M) |
| Financing Cash Flow | 273.37M | 62.08M | (26.65M) | (54.58M) | (61.44M) |
| Effect of Forex Changes | (228K) | 521K | 629K | (2.56M) | 371K |
| Net Change in Cash | 12.37M | (67.38M) | 5.13M | 4.62M | 9.66M |
| Free Cash Flow | 2.1M | (15.02M) | 7.98M | 37.79M | 71.41M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.